{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:52:36Z","timestamp":1753876356358,"version":"3.41.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p\/>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Low forced expiratory volume in 1\u2009s (FEV1) and elevated N-terminal pro-B-type natriuretic peptide (NT-Pro-BNP) have been individually associated with poor outcomes after transcatheter aortic valve replacement (TAVR). We hypothesized a combination of the 2 would provide prognostic indication after TAVR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We categorized 871 patients who received TAVR from 2008 to 2018 into 4 groups according to baseline FEV1 (&amp;lt;60% or \u226560% predicted) and NT-Pro-BNP (&amp;lt;1601 or \u22651601\u2009pg\/ml): group A (n\u2009=\u2009312, high FEV1, low NT-Pro-BNP), group B (n\u2009=\u2009275, high FEV1, high NT-Pro-BNP), group C (n\u2009=\u2009123 low FEV1, low NT-Pro-BNP) and group D (n\u2009=\u2009161, low FEV1, high NT-Pro-BNP). The primary end point was survival at 1 and 5\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Patients in group A had more severe aortic stenosis and achieved the best long-term survival at 1 [93% (95% CI: 90\u201396)] and 5 [45.3% (95% CI: 35.4\u201358)] years. Low FEV1 and high NT-Pro-BNP (group D) patients had more severe symptoms, higher Society of Thoracic Surgeons predicted risk of operative mortality, lower ejection fraction and aortic valve gradient at baseline. Patients in group D had the worst survival at 1 [76% (95% CI: 69\u201383)] and 5 years [13.1% (95% CI: 7\u201325)], hazard ratio compared to group A: 2.29 (95% CI: 1.6\u20133.2, P\u2009&amp;lt;\u20090.001) with 25.7% of patients in New York Heart Association class III\u2013IV. Patients in groups B and C had intermediate outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The combination of FEV1 and NT-Pro-BNP stratifies patients into 4 groups with distinct risk profiles and clinical outcomes. Patients with low FEV1 and high NT-Pro-BNP have increased comorbidities, poor functional outcomes and decreased long-term survival after TAVR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejcts\/ezad017","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T13:27:45Z","timestamp":1673875665000},"source":"Crossref","is-referenced-by-count":0,"title":["The interaction of forced expiratory volume in 1\u2009s and N-terminal pro-B-type natriuretic peptide with outcomes after transcatheter aortic valve replacement"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-1478","authenticated-orcid":false,"given":"Juan A","family":"Crestanello","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin L","family":"Greason","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessey","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackram F","family":"Eleid","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuyisile T","family":"Nkomo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charanjit S","family":"Rihal","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor","family":"Bagameri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorin V","family":"Pislaru","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurpreet S","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-9640","authenticated-orcid":false,"given":"Katherine S","family":"King","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Alkhouli","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"2023042502195928000_ezad017-B1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jacc.2013.09.024","article-title":"Outcomes of patients with chronic lung disease and severe aortic stenosis treated with transcatheter versus surgical aortic valve replacement or standard therapy: insights from the PARTNER trial","volume":"63","author":"Dvir","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023042502195928000_ezad017-B2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/S0140-6736(16)30073-3","article-title":"Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis","volume":"387","author":"Thourani","year":"2016","journal-title":"Lancet"},{"key":"2023042502195928000_ezad017-B3","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.amjcard.2020.02.004","article-title":"Prognostic value of N-terminal Pro-form B-type natriuretic peptide in patients with moderate aortic stenosis","volume":"125","author":"Ito","year":"2020","journal-title":"Am J Cardiol"},{"key":"2023042502195928000_ezad017-B4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.amjcard.2018.11.030","article-title":"Meta-analysis of impact of baseline N-terminal Pro-brain natriuretic peptide levels on survival after transcatheter aortic valve implantation for aortic stenosis","volume":"123","author":"Takagi","year":"2019","journal-title":"Am. J. Cardiol"},{"key":"2023042502195928000_ezad017-B5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamacardio.2015.0326","article-title":"Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement","volume":"1","author":"Edwards","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2023042502195928000_ezad017-B6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2174\/0929867324666170727110241","article-title":"Biomarkers in aortic valve stenosis and their clinical significance in transcatheter aortic valve implantation","volume":"26","author":"Toutouzas","year":"2019","journal-title":"Curr Med Chem"},{"key":"2023042502195928000_ezad017-B7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.yjmcc.2019.03.011","article-title":"Molecular and clinical implications of natriuretic peptides in aortic valve stenosis","volume":"129","author":"Gallo","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"2023042502195928000_ezad017-B8","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jacc.2014.02.581","article-title":"B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival","volume":"63","author":"Clavel","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023042502195928000_ezad017-B9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/eurheartj\/ehz892","article-title":"Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry","volume":"41","author":"Chen","year":"2020","journal-title":"Eur Heart J"},{"key":"2023042502195928000_ezad017-B10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/eurheartj\/ehi631","article-title":"NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study","volume":"27","author":"Januzzi","year":"2006","journal-title":"Eur Heart J"},{"key":"2023042502195928000_ezad017-B11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jchf.2019.12.010","article-title":"Natriuretic peptides as inclusion criteria in clinical trials","volume":"8","author":"Ibrahim","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2023042502195928000_ezad017-B12","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0954-6111(08)70005-2","article-title":"Predictors of survival in COPD: more than just the FEV1","volume":"102","author":"Celli","year":"2008","journal-title":"Respir Med"},{"key":"2023042502195928000_ezad017-B13","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jcin.2017.07.025","article-title":"Long-term health benefit of transcatheter aortic valve replacement in patients with chronic lung disease","volume":"10","author":"Crestanello","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2023042502195928000_ezad017-B14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.amjcard.2015.01.561","article-title":"Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)","volume":"115","author":"O'Neill","year":"2015","journal-title":"Am J Cardiol"},{"key":"2023042502195928000_ezad017-B15","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.amjcard.2015.08.016","article-title":"Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation","volume":"116","author":"Koskinas","year":"2015","journal-title":"Am J Cardiol"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/advance-article-pdf\/doi\/10.1093\/ejcts\/ezad017\/48724102\/ezad017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/63\/4\/ezad017\/50084248\/ezad017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/63\/4\/ezad017\/50084248\/ezad017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T02:20:19Z","timestamp":1682389219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezad017\/6988033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezad017","relation":{},"ISSN":["1873-734X"],"issn-type":[{"type":"electronic","value":"1873-734X"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,1,16]]},"article-number":"ezad017"}}